We’re thrilled to announce a strategic partnership between the University Medical Center Groningen (UMCG) and Visiopharm to advance AI-driven precision pathology. This partnership will establish UMCG as a reference center, showcasing the transformative power of AI in diagnostics and patient care. Our collaboration includes the introduction of an AI-based image analysis workflow for digital pathology, built upon Visiopharm’s Oncotopix® and Qualitopix® platforms. "By joining forces with Visiopharm, we are set to demonstrate the concrete benefits and transformative power of AI in precision pathology," said Dr. Bert van der Vegt, Clinical Pathologist and lead of the Digital Computational Pathology Unit at UMCG. "As a reference center, we're excited about the opportunity to share our journey and experiences, showcasing the tangible improvements in standardization and patient care that this technology brings." Read the news: https://lnkd.in/dwkuvK4w #stayconfident
Visiopharm
Forskning inden for bioteknologi
Hoersholm, Denmark 8.687 følgere
Visiopharm® is a world leader in AI-driven digital precision pathology software.
Om os
We are a leading provider of AI-driven precision pathology software for research and diagnostics. In research, we are a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, we are a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and and can be easily activated and integrated into existing lab workflows. Founded in 2002, we are privately owned and operate internationally with over 750 customer accounts in more than 40 countries. Our company’s headquarters are located in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
- Websted
-
http://www.visiopharm.com
Eksternt link til Visiopharm
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 51-200 medarbejdere
- Hovedkvarter
- Hoersholm, Denmark
- Type
- Privat
- Grundlagt
- 2001
- Specialer
- Cancer Diagnostics, Cancer Research, Image Analysis, Stereology, Quantitative Digital Pathology, Biomarker Development, Tissue Micro Array (TMA) Management, Pathology, Tissue Section Alignment, Digital Pathology og Spatial biology
Beliggenheder
Medarbejdere hos Visiopharm
-
Leif Honda
Innovation, Strategy, & Business Development Leader redrawing the boundaries of healthcare and life sciences with technology and artificial…
-
Martin Bonde
-
Kim Anders Bjerrum
-
James R. Mansfield
Senior VP @ Visiopharm | Pro-bono Editorial Board Member | Phenoplex strategic development, collaborations, and partnerships
Opdateringer
-
Are you at ECP in Florence? Visit us at booth #40! We're eager to connect with you and share some of the exciting advancements we're presenting this year: 1. Fully Integrated PACS Workflows with Proscia, Sectra, and many more. => drop by and get a demo of the workflow within Proscia at our booth! 2. Complete Qualitopix Workflow – from scanning to comprehensive documentation of staining consistency. => did you spot the small Grundium scanner at our counter? 3. Sneak Peak of our new HER2 APP! => Learn all about how our new cell-based HER2 evaluation APP allows confident scoring also of HER2 low cases. Don’t miss out—come see what’s new! Meet Matthew Burke PhD, Rickard Lindelöf, Martin Kristensson, Sonja Gisladottir and Dirk Vossen at our booth. #ECP2024 #ESPCongress
-
If you are at #ECP2024 this weekend, come by our booth to get a Sneak Peak of our new HER2 algorithm - a fully automated single-cell approach for whole slide HER2 IHC quantification aligned with ASCO/CAP guidelines. Recent advancements in antibody-drug conjugates (ADCs) have introduced more nuanced classifications to HER2 IHC scoring, like HER2-low (1+ and 2+ without gene amplification) and even HER2-ultralow (detectable but less than 1+). These classifications, supported by clinical trials such as DESTINY-Breast04 and DESTINY-Breast06, expand treatment options to include therapies like trastuzumab deruxtecan (TDXd) for a broader range of patients. How does our new HER2 algorithm fit in? The new APP offers a nuanced and detailed analysis of HER2 expression, allowing pathologists to more confidently identify HER2-low and HER2-ultralow cases while optimizing the 2+-rate to limit expensive reflex testing. Want to learn more? https://lnkd.in/dMPGP_V7 *Currently available for research purposes only.
-
How can you use Phenoplex to explore complex interactions between tumor and immune cells within the TME? Join our upcoming masterclass to get insights from Dr. Bora Gurel, MD, PhD, and his work at The Institute of Cancer Research! Masterclass: Hyperplex IF Analysis for Tumor Immunology: Our Experience with Visiopharm 🗓️ Date: September 26 🕓 Time: 4 PM CET / 10 AM EST Join an exciting lecture followed by a live Q&A with Dr. Gurel. Register now: https://hubs.ly/Q02qxpLS0 #VisiopharmSpatialSeries #SpatialBiology
-
Today’s #ThursdayDiscovery features research from Gu-Choul Shin et al. highlighting the potential of VUTI, a paraoxonase-2 agonist, in treating non-alcoholic steatohepatitis (NASH). The study demonstrates how VUTI promotes autophagy and improves mitochondrial function to reduce liver fat and fibrosis. Visiopharm software was employed for quantitative histomorphometry in the study, specifically analyzing liver tissue sections stained for various markers, including fat accumulation, fibrosis, and autophagy-related proteins. 👉 Read the full article: https://lnkd.in/dmgnRhtM
-
Why should you consider an AI-software to analyze your NanoString GeoMx DSP images? 🔸 Deciding where to place Regions of Interest (ROIs) and creating Areas of Interest (AOIs) for GeoMx DSP can be quite a challenge and a time- 🔸 consuming process. 🔸 Pathologists typically prefer annotating H&E images and securing pathologist time on the day of a GeoMx experiment is often difficult. 🔸 Picking ROIs can be biased and creating useful AOIs can be challenging with existing tools. The integration of our Oncotopix Discovery software with NanoString GeoMx DSP allows you to automate and simplify these jobs, unlocking data for your research and publications much faster. Learn more about our integration here: https://lnkd.in/dVijyNEt Image credits: Arutha Kulasinghe #SpatialBiology #Geomx NanoString Technologies, Inc.
-
Join us at Agilent’s digital pathology lunch symposium! If you are attending ECP in Florence, this seminar is a great opportunity to grab lunch and learn from digital pathology experts with real-world examples and insights on how scalable, agnostic, end-to-end digital pathology solutions can be effectively utilized to advance pathology labs in practice. Don’t miss the talk from Dr. Bert van der Vegt, Consultant Histopathologist at University Medical Center Groningen & Scientific Advisor of Visiopharm: “Integration of Computational Pathology Algorithms in the Clinical Digital Pathology Workflow: Connecting the Dots”. 📅 Date & time: Tuesday, 10 September 2024 from 13:00-14:30. 📍 Location: Room Spadolini 7 Check out the agenda and register here: https://lnkd.in/dJCyQ58J Research Use Only - not for use in diagnostic procedures. Agilent Technologies does not provide support in the validation of Research Use Only products for clinical use. Agilent Technologies #ECP2024 European Society of Pathology #stayconfident
-
Identifying lymph node (LN) metastasis in invasive breast carcinoma can be tedious and time-consuming. But what if AI algorithms could help? 💡 The pathology team at The Ohio State University published a study investigating the effectiveness of Visiopharm’s AI algorithm for detecting LN metastasis in patients with invasive breast carcinoma using H&E slides in a clinical digital workflow. ✅ The algorithm achieved 100% sensitivity in detecting lymph node metastasis in breast cancer and significantly reduced the time pathologists spent reviewing slides. Read the article here: https://lnkd.in/dPDYQedh Authors: Bindu Challa ∙ Maryam Tahir ∙ Yan Hu ∙ David Kellough ∙ Giovanni Lujan MD ∙ Shaoli Sun ∙ Anil Parwani ∙ Zaibo Li 👉 Interested in learning more? Join us at the 2024 OSU Pathology Update Course and Digital Pathology Workshop on September 12-14 with Amanda L. & Dan Hoerich! Registration is open: https://lnkd.in/dC88p4-C
-
Visiopharm is excited to sponsor and participate in the upcoming symposium with Bio-Trac®, featuring top experts in pathology, spatial biology, multiplex immunofluorescence, AI, and translational medicine. 📅 September 9-10, 2024 📍 Germantown, MD at the Bioscience Education Center Don't miss this chance to connect with Regan Baird and learn more about #Phenoplex, our complete workflow for multiplex image analysis. More info here: https://lnkd.in/eZEegqGM https://lnkd.in/eZEegqGM
-
Discover the latest research published in Nature Communications on the effects of Zika virus exposure during pregnancy. Jenny Go et al. have presented findings on the impact of prenatal Zika virus (ZikV) exposure on the development of fetal brain structures, with a specific focus on myelin and oligodendrocyte maturation. The team utilized Visiopharm's image analysis software for quantitative analysis of immunohistochemical data. The software helped in the precise quantification of myelin-related proteins and the assessment of myelin sheath integrity in fetal brain tissue. Read the full article: https://lnkd.in/dfBXhCKw #ThursdayDiscovery #OncotopixDiscovery